EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2026 Interim Results at a glance

2026.08.05

H1 2026 Results Announcement: Regulatory Headwinds Drag Down, Revenue by 10.5% to HK$784.7 million and Profit by 32.2% to HK$110.7 million, Interim Dividend HK$0.05

2026.08.05

Essex Bio-Technology enters Strategic Collaboration Framework Agreement with Gunze Medical to further Commercial Access and to advance Research in Regenerative Medicine and Wound Care

2026.07.23

Date

Title

2025-12-17

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025-11-21

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025-08-26

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025-08-26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

2025-08-13

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025-07-24

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

2025-04-02

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025-03-26

Essex Bio-Technology (1061.HK) 2024 Annual Results at a glance

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT